免疫疗法的兴起为癌症治疗提供了新的方法。我们的目的是描述嵌合抗原受体 T 细胞免疫疗法对未来前景的贡献。我们使用 CiteSpace 分析了 Web of Science 核心合集中的 8035 篇文章，涵盖国家、机构、作者、共同被引作者、期刊、关键词和参考文献的各个方面。美国是最多产的国家，宾夕法尼亚大学是出版最多的机构。在个人作者中，June Carl H 发表的文章最多，而 Maude SL 是最常被共同引用的作者。 《Blood》成为被引用最多的期刊。关键词聚类揭示了六个核心主题：“表达”、“嵌合抗原受体”、“肿瘤微环境”、“Blinatumomab”、“多发性骨髓瘤”和“细胞因子释放综合征”。在研究关键词和参考文献的时间线图的过程中，“大B细胞淋巴瘤”位于时间线的右侧。在关键词显着性分析中，我们发现关键词“生物标志物”、“pd-1”、“抗体药物偶联物”、“BCMA”、“嵌合抗原”近期爆发强度较高。我们发现，就相关疾病而言，“大B细胞淋巴瘤”和“细胞因子释放综合征”仍然是未来的难题。在治疗方法的研究中，“BCMA”、“PD-1”、“嵌合抗原”、“抗体药物偶联物”未来值得研究者更多关注。© 2024。作者，独家许可德国施普林格出版社 (Springer-Verlag GmbH)，隶属于施普林格自然集团。

The rise of immunotherapy provided new approaches to cancer treatment. We aimed to describe the contribution of chimeric antigen receptor T cell immunotherapy to future prospects. We analyzed 8035 articles from the Web of Science Core Collection with CiteSpace that covered with various aspects with countries, institutions, authors, co-cited authors, journals, keywords, and references. The USA was the most prolific country, with the University of Pennsylvania being the most published institution. Among individual authors, June Carl H published the most articles, while Maude SL was the most frequently co-cited author. "Blood" emerged as the most cited journal. Keyword clustering revealed six core themes: "Expression," "Chimeric Antigen Receptor," "Tumor Microenvironment," "Blinatumomab," "Multiple Myeloma," and "Cytokine Release Syndrome." In the process of researching the timeline chart of keywords and references, "Large B-cell lymphoma" was located on the right side of the timeline. In the keyword prominence analysis, we found that the keywords "biomarkers," "pd-1," "antibody drug conjugate," "BCMA," and "chimeric antigen" had high explosive intensity in the recent past. We found that in terms of related diseases, "large B-cell lymphoma" and "cytokine release syndrome" are still difficult problems in the future. In the study of therapeutic methods, "BCMA," "PD-1," "chimeric antigen," and "antibody drug conjugate" deserve more attention from researchers in the future.© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.